Nifedipine Relonchem

Nifedipine, the active ingredient in Nifedipine Relonchem, is a calcium channel blocker presented as an oral tablet for oral use. It belongs to the dihydropyridine subclass and is used to treat hypertension, chronic stable angina, and Raynaud's phenomenon in adult patients by relaxing vascular smooth muscle and improving coronary blood flow.

GNH USA supplies Nifedipine Relonchem as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide and ensuring regulatory compliance in each market.

Nifedipine is a calcium channel blocker indicated for several cardiovascular and peripheral vascular conditions.

Hypertension: reduces elevated blood pressure by inducing peripheral vasodilation. Chronic stable angina: alleviates chest pain by improving coronary blood flow. Raynaud's phenomenon: diminishes frequency and severity of vasospastic attacks in peripheral arteries.

Nifedipine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache often occurring at treatment initiation. - Flushing: transient facial or upper body warmth and redness. - Peripheral edema: swelling of ankles or lower legs due to fluid accumulation. - Dizziness: light‑headedness, especially when standing quickly. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Myocardial infarction: rare occurrence of heart attack, particularly in patients with pre‑existing coronary disease. - Atrioventricular block: conduction disturbances requiring medical attention. - Hepatotoxicity: abnormal liver function tests indicating possible liver injury. - Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals.

Before prescribing Nifedipine, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: evaluate for severe aortic stenosis or heart failure before initiation. - Concomitant nitrates: avoid co‑administration as it may cause profound hypotension. - Liver impairment: use lower doses and monitor hepatic function in patients with hepatic disease. - Elderly patients: start with the lowest effective dose and monitor for orthostatic hypotension. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Nifedipine can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nifedipine plasma levels, risking toxicity. - Grapefruit juice: can significantly increase drug concentration, leading to severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering plasma concentrations. - Beta‑blockers: combined use may enhance antihypertensive effect, requiring blood pressure monitoring. - Diuretics: may potentiate orthostatic hypotension; adjust dosing as needed.